Shanghai Pharmaceutical Co Ltd (601607)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Shanghai Pharmaceutical Co Ltd (601607) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014374
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. It carries out the research and development, manufacture and sale of pharmaceutical products for treating cancer, central nervous system (CNS) disorders and diseases related to digestive system and immuno-metabolism, cardio and cerebrovascular system and infection. The company also provides distribution and supply chain solutions to pharmaceutical manufacturers and dispensers; operates retail pharmacy stores; and provides consulting services, assets management and other services. In addition, Shanghai Pharma provides traditional Chinese medicines. The company operates through a group of subsidiaries across China. Shanghai Pharma is headquartered in Shanghai, China.

Shanghai Pharmaceutical Co Ltd (601607) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Shanghai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Shanghai Pharma to Acquire China Business from Cardinal Health for USD1.2 Billion 13
Partnerships 15
Shanghai Fudan-Zhangjiang Renews Strategic Cooperation Agreement with Shanghai Pharmaceuticals 15
Shanghai Pharma to Form Joint Venture with Zhongxie Pharma 16
Shanghai Traditional Chinese Medicine Enters into Distribution Agreement with Shanghai Hutchison Pharma for Six Prescription Drug Products 17
Shanghai Pharma Enters Into R&D Agreement With Second Military Medical University To Develop New Medicine And Medical Devices 18
Pfizer Signs MOU To Form Joint Venture With Shanghai Pharma 19
Equity Offering 20
Adgero Biopharma Raises USD2 Million in Equity Financing 20
Shanghai Fudan-Zhangjiang Completes Private Placement Of Shares For US$25 Million 21
Shanghai Pharma Completes IPO For US$1.95 Billion 22
Acquisition 24
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 24
Shanghai Pharma Plans to Acquire 67.5% Stake in Yunnan Dali Kangya Biotech for USD43.8 Million 25
Shanghai Pharmaceuticals Acquires Stakes in Two China-Based Pharma Companies for USD71 Million 26
Shanghai Pharma To Acquire Drug Development Company For US$2.4 Million 27
Shanghai Pharma To Acquire China International Pharma For Up To US$8 Million 28
Shanghai Pharma Acquires 79% Stake In Big Global From Dongying Pharma For US$99 Million 29
Shanghai No.1 Biochemical & Pharma Acquires Additional 10.99% Stake In Mergen Biotech From Excellent Hope For US$0.2 Million 30
Shanghai Pharma To Acquire Additional 20% Stake In Chiatai Qingchun Bao Pharma For US$71 Million 31
Shanghai Pharma Completes Acquisition Of 70% Stake In Changzhou Kangli Pharma For US$33 Million 32
Shanghai Zhongxi Sunve Pharma Acquires 51% Stake In Shanghai Jinhe Bio-Technology 33
Shanghai Pharma Acquires 80% Stake In Wuxi Shanhe Pharma 34
Shanghai Pharma To Acquire A Drug Company 35
Shanghai Pharma Completes Acquisition Of 65.2% Stake In China Health System 36
Shanghai Pharma Completes Acquisition Of Remaining 34.8% Stake In CITIC Pharma For US$540 Million 37
Shanghai Pharmaceutical Co Ltd – Key Competitors 38
Shanghai Pharmaceutical Co Ltd – Key Employees 39
Shanghai Pharmaceutical Co Ltd – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 42
Financial Announcements 42
Oct 30, 2017: Shanghai Pharmaceuticals Realized Stable Results In the Third Quarter 42
Aug 28, 2017: Shanghai Pharmaceuticals Realized Stable and Healthy Growth in Interim Results 43
Jun 27, 2017: Shanghai Pharmaceuticals Grew Steady in 2017 Q1 45
Mar 21, 2016: Shanghai Pharma’s 2015 Results Released 46
Corporate Communications 47
Oct 21, 2016: Shanghai Pharmaceuticals Holding Announces Changes Of The Chairman Of The Board, Member Of The Nomination Committee Of the Board And the Authorised Representative Of the Company 47
Aug 26, 2016: Shanghai Pharmaceuticals Holding Announces Resignation Of Executive Director And Proposed Appointment Of Director 49
May 07, 2016: Shanghai Pharmaceuticals Holding Announces Resignation Of Executive Director 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Shanghai Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Shanghai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Shanghai Pharma to Acquire China Business from Cardinal Health for USD1.2 Billion 13
Shanghai Fudan-Zhangjiang Renews Strategic Cooperation Agreement with Shanghai Pharmaceuticals 15
Shanghai Pharma to Form Joint Venture with Zhongxie Pharma 16
Shanghai Traditional Chinese Medicine Enters into Distribution Agreement with Shanghai Hutchison Pharma for Six Prescription Drug Products 17
Shanghai Pharma Enters Into R&D Agreement With Second Military Medical University To Develop New Medicine And Medical Devices 18
Pfizer Signs MOU To Form Joint Venture With Shanghai Pharma 19
Adgero Biopharma Raises USD2 Million in Equity Financing 20
Shanghai Fudan-Zhangjiang Completes Private Placement Of Shares For US$25 Million 21
Shanghai Pharma Completes IPO For US$1.95 Billion 22
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 24
Shanghai Pharma Plans to Acquire 67.5% Stake in Yunnan Dali Kangya Biotech for USD43.8 Million 25
Shanghai Pharmaceuticals Acquires Stakes in Two China-Based Pharma Companies for USD71 Million 26
Shanghai Pharma To Acquire Drug Development Company For US$2.4 Million 27
Shanghai Pharma To Acquire China International Pharma For Up To US$8 Million 28
Shanghai Pharma Acquires 79% Stake In Big Global From Dongying Pharma For US$99 Million 29
Shanghai No.1 Biochemical & Pharma Acquires Additional 10.99% Stake In Mergen Biotech From Excellent Hope For US$0.2 Million 30
Shanghai Pharma To Acquire Additional 20% Stake In Chiatai Qingchun Bao Pharma For US$71 Million 31
Shanghai Pharma Completes Acquisition Of 70% Stake In Changzhou Kangli Pharma For US$33 Million 32
Shanghai Zhongxi Sunve Pharma Acquires 51% Stake In Shanghai Jinhe Bio-Technology 33
Shanghai Pharma Acquires 80% Stake In Wuxi Shanhe Pharma 34
Shanghai Pharma To Acquire A Drug Company 35
Shanghai Pharma Completes Acquisition Of 65.2% Stake In China Health System 36
Shanghai Pharma Completes Acquisition Of Remaining 34.8% Stake In CITIC Pharma For US$540 Million 37
Shanghai Pharmaceutical Co Ltd, Key Competitors 38
Shanghai Pharmaceutical Co Ltd, Key Employees 39
Shanghai Pharmaceutical Co Ltd, Subsidiaries 40

★海外企業調査レポート[Shanghai Pharmaceutical Co Ltd (601607)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Iovance Biotherapeutics Inc (IOVA):製薬・医療:M&Aディール及び事業提携情報
    Summary Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead pr …
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes medicines for the treatment of epilepsy and other neuropsychiatric disorders. The company is evaluating its lead product candidate Ganaxolone, a gamma-aminobutyri …
  • London North West Healthcare NHS Trust:企業の戦略的SWOT分析
    London North West Healthcare NHS Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Civica Group Limited:企業の戦略的SWOT分析
    Civica Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mangalore Refinery and Petrochemicals Ltd (MRPL):企業の財務・戦略的SWOT分析
    Mangalore Refinery and Petrochemicals Ltd (MRPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Global Marine Systems Ltd-エネルギー分野:企業M&A・提携分析
    Summary Global Marine Systems Limited (Global Marine), a subsidiary of Bridgehouse Marine Limited, is a marine technology and engineering company. It provides submarine cable installation, maintenance and engineering services. Its capabilities include project management, subsea cable installation, s …
  • Janssen Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a healthcare products provider that offers various medicines. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental …
  • Radiation Monitoring Devices Inc:製品パイプライン分析
    Summary Radiation Monitoring Devices Inc (RMD), a subsidiary of Dynasil Corporation of America is a research and development company that provides solutions for security, medical and industrial applications. The company’s products include scintillators, APDs, cesium iodide, solid state photomultipli …
  • Eli Lilly and Company (India) Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Eli Lilly and Company (India) Pvt Ltd (Eli Lilly), a subsidiary of Eli Lilly and Company is a drug company that manufactures medicines. The company offers pharmaceutical products for the therapeutic areas such as diabetes, cancer, osteoporosis, cardiovascular disorders and growth-hormone def …
  • Television Francaise 1 SA:企業の戦略・SWOT・財務分析
    Television Francaise 1 SA - Strategy, SWOT and Corporate Finance Report Summary Television Francaise 1 SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Eguana Technologies Inc. (EGT):企業の財務・戦略的SWOT分析
    Eguana Technologies Inc. (EGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • ALK-Abello AS (ALK B)-製薬・医療分野:企業M&A・提携分析
    Summary ALK-Abello A/S (ALK) is a research-oriented pharmaceutical company, which discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It also markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio incl …
  • Factor Therapeutics Ltd (FTT)-製薬・医療分野:企業M&A・提携分析
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor w …
  • GAMCO Investors, Inc.:企業の戦略・SWOT・財務情報
    GAMCO Investors, Inc. - Strategy, SWOT and Corporate Finance Report Summary GAMCO Investors, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Kotak Wealth Management:企業の戦略・SWOT・財務情報
    Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Tata Advanced Systems Ltd:企業の戦略・SWOT・財務情報
    Tata Advanced Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Tata Advanced Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Transat A.T. Inc:企業の戦略・SWOT・財務情報
    Transat A.T. Inc - Strategy, SWOT and Corporate Finance Report Summary Transat A.T. Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • HDFC Standard Life Insurance Company Limited:企業の戦略・SWOT・財務情報
    HDFC Standard Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary HDFC Standard Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • TUI AG (TUI1):企業の財務・戦略的SWOT分析
    TUI AG (TUI1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Godrej Agrovet Limited (GODREJAGRO):企業の財務・戦略的SWOT分析
    Godrej Agrovet Limited (GODREJAGRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆